Means Investment CO. Inc. reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 7.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,701 shares of the company’s stock after selling 231 shares during the quarter. Means Investment CO. Inc.’s holdings in Eli Lilly And Co were worth $350,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. KMG Fiduciary Partners LLC boosted its holdings in shares of Eli Lilly And Co by 6.3% in the first quarter. KMG Fiduciary Partners LLC now owns 4,086 shares of the company’s stock worth $530,000 after buying an additional 243 shares during the last quarter. Tower View Investment Management & Research LLC lifted its holdings in Eli Lilly And Co by 15,224.8% during the first quarter. Tower View Investment Management & Research LLC now owns 24,060 shares of the company’s stock valued at $3,122,000 after purchasing an additional 23,903 shares in the last quarter. Steinberg Global Asset Management purchased a new position in Eli Lilly And Co during the first quarter valued at approximately $309,000. Palisade Asset Management LLC lifted its holdings in Eli Lilly And Co by 3.9% during the first quarter. Palisade Asset Management LLC now owns 26,359 shares of the company’s stock valued at $3,420,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Flagship Harbor Advisors LLC lifted its holdings in Eli Lilly And Co by 54.8% during the first quarter. Flagship Harbor Advisors LLC now owns 3,133 shares of the company’s stock valued at $406,000 after purchasing an additional 1,109 shares in the last quarter. Institutional investors and hedge funds own 79.17% of the company’s stock.
In related news, SVP Enrique A. Conterno sold 25,000 shares of the stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $121.00, for a total value of $3,025,000.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Aarti S. Shah sold 1,800 shares of the stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $125.85, for a total transaction of $226,530.00. Following the completion of the transaction, the senior vice president now owns 18,425 shares in the company, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 870,959 shares of company stock worth $109,672,752. Corporate insiders own 0.11% of the company’s stock.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.31 earnings per share. As a group, equities analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be issued a dividend of $0.645 per share. The ex-dividend date is Thursday, May 16th. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 46.49%.
Several equities analysts have weighed in on the stock. TheStreet downgraded shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday. BMO Capital Markets lifted their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective on the stock in a research report on Tuesday, April 23rd. Finally, Barclays reiterated a “buy” rating and set a $140.00 price objective on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $118.83.
WARNING: “Means Investment CO. Inc. Sells 231 Shares of Eli Lilly And Co (NYSE:LLY)” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/11/means-investment-co-inc-has-350000-holdings-in-eli-lilly-and-co-lly.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: The Structure of a Futures Contract
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.